Citations

Clear

2303 citation(s) found for "Yu, Edward".

Geographical variability and environmental risk factors in inflammatory bowel disease
Ng, Siew C. , Bernstein, Çharles N. , Vatn, Morten H., Lakatos, Péter L. , Loftus, Edward V. , Tysk, Curt , O’Morain, Colm, Bernstein, Charles Noah , Moum, Bjørn Allan , Colombel, Jean‐Frédéric , Loftus, Edward V , Ng, Siew C , Lakatos, Peter L

Mayo Clinic

Gut | January 18, 2013 | Volume: 62 | Issue: 4 | Pages: 630-649

10.1136/gutjnl-2012-303661 | PMID 23335431 Get It

The changing epidemiology of inflammatory bowel disease (IBD) across time and geography suggests that environmental factors play a major role in modifying disease expression. Disease emergence in developing nations suggests that epidemiological evolution is related to westernisation of lifestyle and industrialisation. The strongest environmental associations identified are cigarette smoking and appendectomy, although neither alone explains the variation in incidence of IBD worldwide. Urbanisation of societies, associated with changes in diet, antibiotic use, hygiene status, microbial exposures and pollution have been implicated as potential environmental risk factors for IBD. Changes in socioeconomic status might occur differently in different geographical areas and populations and, consequently, it is important to consider the heterogeneity of risk factors applicable to the individual patient. Environmental risk factors of individual, familial, community-based, country-based and regionally based origin may all contribute to the pathogenesis of IBD. The geographical variation of IBD provides clues for researchers to investigate possible environmental aetiological factors. The present review aims to provide an update of the literature exploring geographical variability in IBD and to explore the environmental risk factors that may account for this variability.
Staged Versus One-time Complete Revascularization With Percutaneous Coronary Intervention for Multivessel Coronary Artery Disease Patients Without ST-Elevation Myocardial Infarction
Samadashvili, Zaza, Walford, Gary, Jacobs, Alice K. , Stamato, Nicholas J., Venditti, Ferdinand J. , Holmes, David R. , Sharma, Samin K. , King, Spencer B., Hannan, Edward L.

Mayo Clinic

Circulation: Cardiovascular Interventions | January 16, 2013 | Volume: 6 | Issue: 1 | Pages: 12-20

10.1161/circinterventions.112.974485 | PMID 23322743 Get It

Background— There are evidence-based guidelines for staging of patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), but we are not aware of any evidence comparing the strategy of complete revascularization (CR) with PCI in the index admission versus the strategy of staging in a subsequent admission for patients with coronary artery disease without STEMI. Methods and Results— PCI patients without STEMI undergoing PCI in New York between 2007 and 2009 were separated into 2 groups: those with acute coronary syndrome but no STEMI, and those without acute coronary syndrome. For each group, patients who underwent CR in the index admission were then propensity matched to patients staged within 60 days to obtain CR based on 17 patient risk factors related to longer-term mortality, and 3-year mortality rates were compared for the propensity-matched groups. Outcomes were also compared for preselected subgroups. For propensity-matched patients without acute coronary syndrome, the all-cause mortality rates at 3 years for patients who underwent CR in the index hospitalization and patients staged for CR within 60 days of discharge were 5.62% and 5.97%, P =0.93, respectively. For propensity-matched patients with acute coronary syndrome but without STEMI, the all-cause mortality rates at 3 years for patients who underwent CR in the index hospitalization and patients staged for CR within 60 days of discharge were 6.59% and 5.92%, P =0.41, respectively. Conclusions— Patients with coronary artery disease without STEMI do not have significantly lower 3-year mortality rates with staged PCI than when they undergo CR in the index admission.
Neurodevelopmental Disabilities in Children With Intermediate and Premutation Range Fragile X Cytosine-Guanine-Guanine Expansions
Renda, Meredith M., Voigt, Robert G. , Babovic‐Vuksanovic, Dusica , Highsmith, W. Edward, Vinson, Sherry, Sadowski, Christine M., Hagerman, Randi J.

Mayo Clinic

Journal of Child Neurology | December 24, 2012 | Volume: 29 | Issue: 3 | Pages: 326-330

10.1177/0883073812469723 | PMID 23266944 Get It

To determine the range of neurodevelopmental diagnoses associated with intermediate (45-54 repeats) and premutation (55-200 repeats) range cytosine-guanine-guanine fragile X expansions, the medical records of children with intermediate or premutation range expansions were retrospectively reviewed, and all neurodevelopmental diagnoses were abstracted. Twenty-nine children (9 female, 20 male; age, 13 months to 17 years) with intermediate (n = 25) or premutation (n = 4) range expansions were identified with neurodevelopmental diagnoses, including global developmental delay/intellectual disability (n = 15), language and learning disorders (n = 9), attention-deficit hyperactivity disorder (n = 5), epilepsy (n = 5), and motor disorders (n = 12), including 2 boys younger than 4 years of age with tremor and ataxia. Thus, children with intermediate or premutation range fragile X cytosine-guanine-guanine expansions may be more susceptible than children without such expansions to other processes, both genetic and environmental, that contribute to neurodevelopmental disability.
Traffic Jam at the Blood–Brain Barrier Promotes Greater Accumulation of Alzheimer’s Disease Amyloid-β Proteins in the Cerebral Vasculature
Agyare, Edward K., Leonard, Sarah R., Curran, Geoffry L., Yu, Caroline C., Lowe, Val J. , Poduslo, Joseph F., Kandimalla, Karunya K. , Paravastu, Anant K. , Kandimalla, Karunya K

Mayo Clinic

Molecular Pharmaceutics | December 18, 2012 | Volume: 10 | Issue: 5 | Pages: 1557-1565

10.1021/mp300352c | PMID 23249146 Get It

Risk Factors for Development of Acute Kidney Injury in Critically Ill Patients: A Systematic Review and Meta-Analysis of Observational Studies
Cartin‐Ceba, Rodrigo , Kashiouris, Markos , Plataki, Maria , Kor, Daryl J. , Casey, Edward T., Gajic, Ognjen

Mayo Clinic

Critical Care Research and Practice | November 26, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-15

10.1155/2012/691013 | PMID 23227318 Get It

Background. Acute kidney injury (AKI) is a frequent complication of critically ill patients. The impact of different risk factors associated with this entity in the ICU setting is unknown.Objectives. The purpose of this research was to assess the risk factors associated with the development of AKI in critically ill patients by meta-analyses of observational studies.Data Extraction. Two reviewers independently and in duplicate used a standardized form to collect data from published reports. Authors were contacted for missing data. The Newcastle-Ottawa scale assessed study quality.Data Synthesis. Data from 31 diverse studies that enrolled 504,535 critically ill individuals from a wide variety of ICUs were included. Separate random-effects meta-analyses demonstrated a significantly increased risk of AKI with older age, diabetes, hypertension, higher baseline creatinine, heart failure, sepsis/systemic inflammatory response syndrome, use of nephrotoxic drugs, higher severity of disease scores, use of vasopressors/inotropes, high risk surgery, emergency surgery, use of intra-aortic balloon pump, and longer time in cardiopulmonary bypass pump.Conclusion. The best available evidence suggests an association of AKI with 13 different risk factors in subjects admitted to the ICU. Predictive models for identification of high risk individuals for developing AKI in all types of ICU are required.
Genome-wide association study of survival in patients with pancreatic adenocarcinoma
Wu, Chen , Steplowski, Emily, Brotzman, Michelle, Xu, Mousheng, Mudgal, Poorva, Ámundadóttir, Laufey T. , Arslan, Alan A. , Bueno‐de‐Mesquita, H. Bas, Gross, Myron D., Helzlsouer, Kathy J., Jacobs, Eric J. , Petersen, Gloria M. , Zheng, Wei , Buring, Julie E. , Canzian, Federico , Cao, Guangwen , Duell, Eric J. , Elena, Joanne W. , Gaziano, J. Michael , Giovannucci, Edward L. , Hallmans, Göran, Hutchinson, Amy , Hunter, David J., Jenab, Mazda , Jiang, Guoliang , LaCroix, Andrea Z. , Li, Zhaoshen , Mendelsohn, Julie B., Panico, Salvatore , Patel, Alpa V. , Qian, Zhi Rong , Ríboli, Elio , Sesso, Howard D. , Shen, Hongbing , Shu, Xiao‐Ou , Tjønneland, Anne , Tobias, Geoffrey S. , Trichopoulos, Dimitrios, Virtamo, Jarmo, Visvanathan, Kala , Wactawski‐Wende, Jean , Wang, Chengfeng , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Hartge, Patricia, Fuchs, Charles S. , Lin, Dongxin , Wolpin, Brian M. , Kraft, Peter , Stolzenberg‐Solomon, Rachael Z. , Kooperberg, Charles , Albanes, Demetrius , Boutron‐Ruault, Marie‐Christine , Khaw, Kay‐Tee , Chanock, Stephen Jacob , Amundadottir, Laufey , Duell, Eric J , Arslan, Alan A , Canzian, Federico , Tjønneland, Anne , Wactawski-Wende, Jean , Shu, Xiao-Ou , Visvanathan, Kala , Jenab, Mazda , Zheng, Wei , Cao, Guangwen , Riboli, Elio , Zeleniuch-Jacquotte, Anne , Shen, Hongbing

Mayo Clinic

Gut | November 24, 2012 | Volume: 63 | Issue: 1 | Pages: 152-160

10.1136/gutjnl-2012-303477 | PMID 23180869 Get It

Background and objective Survival of patients with pancreatic adenocarcinoma is limited and few prognostic factors are known. We conducted a two-stage genome-wide association study (GWAS) to identify germline variants associated with survival in patients with pancreatic adenocarcinoma. Methods We analysed overall survival in relation to single nucleotide polymorphisms (SNPs) among 1005 patients from two large GWAS datasets, PanScan I and ChinaPC. Cox proportional hazards regression was used in an additive genetic model with adjustment for age, sex, clinical stage and the top four principal components of population stratification. The first stage included 642 cases of European ancestry (PanScan), from which the top SNPs (p≤10 −5 ) were advanced to a joint analysis with 363 additional patients from China (ChinaPC). Results In the first stage of cases of European descent, the top-ranked loci were at chromosomes 11p15.4, 18p11.21 and 1p36.13, tagged by rs12362504 (p=1.63×10 −7 ), rs981621 (p=1.65×10 −7 ) and rs16861827 (p=3.75×10 −7 ), respectively. 131 SNPs with p≤10 −5 were advanced to a joint analysis with cases from the ChinaPC study. In the joint analysis, the top-ranked SNP was rs10500715 (minor allele frequency, 0.37; p=1.72×10 −7 ) on chromosome 11p15.4, which is intronic to the SET binding factor 2 (SBF2) gene. The HR (95% CI) for death was 0.74 (0.66 to 0.84) in PanScan I, 0.79 (0.65 to 0.97) in ChinaPC and 0.76 (0.68 to 0.84) in the joint analysis. Conclusions Germline genetic variation in the SBF2 locus was associated with overall survival in patients with pancreatic adenocarcinoma of European and Asian ancestry. This association should be investigated in additional large patient cohorts.
ACR Appropriateness Criteria ® Spinal Bone Metastases
Lo, Simon Shek-Man, Lutz, Stephen, Chang, Eric L. , Galanopoulos, Nicholas, Howell, David D., Kim, Edward Y. , Konski, André , Pandit-Taskar, Neeta D., Rose, Peter S. , Ryu, Samuel , Silverman, Larry N., Sloan, Andrew E. , Poznak, Catherine Van

Mayo Clinic

Journal of Palliative Medicine | November 20, 2012 | Volume: 16 | Issue: 1 | Pages: 9-19

10.1089/jpm.2012.0376 | PMID 23167547 Get It

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Cairncross, Gregory, Wang, Meihua , Shaw, Edward , Jenkins, Robert B. , Brachman, David, Buckner, Jan C. , Fink, Karen, Souhami, Luís, Laperrière, Normand , Curran, Walter, Mehta, Minesh P. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | October 16, 2012 | Volume: 31 | Issue: 3 | Pages: 337-343

10.1200/jco.2012.43.2674 | PMID 23071247 Get It

Purpose Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown. Patients and Methods Eligible patients with AO/AOA were randomly assigned to procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) versus RT alone. The primary end point was overall survival (OS). Results Two hundred ninety-one eligible patients were randomly assigned: 148 to PCV plus RT and 143 to RT. For the entire cohort, there was no difference in median survival by treatment (4.6 years for PCV plus RT v 4.7 years for RT; hazard ratio [HR] = 0.79; 95% CI, 0.60 to 1.04; P = .1). Patients with codeleted tumors lived longer than those with noncodeleted tumors (PCV plus RT: 14.7 v 2.6 years, HR = 0.36, 95% CI, 0.23 to 0.57, P < .001; RT: 7.3 v 2.7 years, HR = 0.40, 95% CI, 0.27 to 0.60, P < .001), and the median survival of those with codeleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.7 v 7.3 years; HR = 0.59; 95% CI, 0.37 to 0.95; P = .03). For those with noncodeleted tumors, there was no difference in median survival by treatment arm (2.6 v 2.7 years; HR = 0.85; 95% CI, 0.58 to 1.23; P = .39). In Cox models that included codeletion status, the adjusted OS for all patients was prolonged by PCV plus RT (HR = 0.67; 95% CI, 0.50 to 0.91; P = .01). Conclusion For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
Boxer, Adam L. , Huey, Edward D. , Hu, William T. , Rosen, Howard J. , Kramer, Joel H. , Gao, Fen‐Biao , Burton, Edward A. , Chow, Tiffany W. , Leavitt, Blair R. , Lamb, Bruce T. , Grether, Megan, Cairns, Nigel J., Mackenzie, Ian R. , Mitic, Laura L. , Roberson, Erik D. , Kammen, Daniel van, Cantillon, Marc, Zahs, Kathleen R. , Jackson, George R. , Salloway, Stephen , Morris, John C. , Tong, Gary, Feldman, Howard , Fillit, Howard , Dickinson, Susan, Khachaturian, Zaven S., Sutherland, Margaret , Abushakra, Susan, Lewcock, Joseph W. , Farese, Robert V. , Kenet, Robert O. , LaFerla, Frank M. , Perrin, Steve, Whitaker, Steve, Grossman, Murray, Gold, Michael , Kao, Aimee W. , Knopman, David S. , Honig, Lawrence S. , Mesulam, Marsel M. , Boeve, Bradley F. , Miller, Bruce L. , Cummings, Jeffrey L. , Roberson, Erik , Morris, John C , Feldman, Howard H , Hu, William T.

Mayo Clinic

Alzheimer's & Dementia | October 10, 2012 | Volume: 9 | Issue: 2 | Pages: 189-198

10.1016/j.jalz.2012.03.003 | PMID 23062850 Get It

Frontotemporal degeneration (FTD) encompasses a spectrum of related neurodegenerative disorders with behavioral, language, and motor phenotypes for which there are currently no effective therapies. This is the second of two articles that summarize the presentations and discussions that occurred at two symposia in 2011 sponsored by the Frontotemporal Degeneration Treatment Study Group, a collaborative group of academic and industry researchers that is devoted to developing treatments for FTD. This article discusses the current status of FTD clinical research that is relevant to the conduct of clinical trials, and why FTD research may be an attractive pathway for developing therapies for neurodegenerative disorders. The clinical and molecular features of FTD, including rapid disease progression and relatively pure molecular pathology, suggest that there are advantages to developing drugs for FTD as compared with other dementias. FTD qualifies as orphan indication, providing additional advantages for drug development. Two recent sets of consensus diagnostic criteria will facilitate the identification of patients with FTD, and a variety of neuropsychological, functional, and behavioral scales have been shown to be sensitive to disease progression. Moreover, quantitative neuroimaging measurements demonstrate progressive brain atrophy in FTD at rates that may surpass Alzheimer's disease. Finally, the similarities between FTD and other neurodegenerative diseases with drug development efforts already underway suggest that FTD researchers will be able to draw on this experience to create a road map for FTD drug development. We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies.
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
Boxer, Adam L. , Huey, Edward D. , Gao, Fen‐Biao , Burton, Edward A. , Chow, Tiffany W. , Leavitt, Blair R. , Lamb, Bruce T. , Grether, Megan, Cairns, Nigel J. , Mackenzie, Ian R. , Mitic, Laura L. , Roberson, Erik D. , Kammen, Daniel van, Cantillon, Marc, Zahs, Kathleen R. , Salloway, Stephen , Morris, John C. , Tong, Gary, Feldman, Howard , Fillit, Howard , Dickinson, Susan, Khachaturian, Zaven S., Sutherland, Margaret , Farese, Robert V. , Gold, Michael , Kao, Aimee W. , Knopman, David S. , Miller, Bruce L. , Cummings, Jeffrey L. , Roberson, Erik , Morris, John C , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | October 5, 2012 | Volume: 9 | Issue: 2 | Pages: 176-188

10.1016/j.jalz.2012.03.002 | PMID 23043900 Get It

Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled “FTD, the Next Therapeutic Frontier,” which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.